X-PATH
LIVE

Serial Number

88333627

Owner

Essenlix Corporation

Attorney

Xiongying Tu

Filing Date

Mar 11, 2019

Add to watchlist:

No watchlists yet
View on USPTO

X-PATH Trademark

Serial Number: 88333627 • Registration: 6880311

X-PATH is a trademark filed by Essenlix Corporation on March 11, 2019. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Essenlix Corporation (147 trademarks)

7 Foulet Dr
Princeton, CA 08540

Entity Type: 03

Trademark Details

Filing Date

March 11, 2019

Registration Date

October 18, 2022

Published for Opposition

December 10, 2019

Goods & Services

Assays for research purposes; Biological and chemical reagents used for non-medical research and laboratory purposes, in vitro and in vivo scientific use, the testing of bodily fluids, and the detecting and analyzing of cells, proteins, small molecules, and nucleotides; Biological and chemical test kits comprised of biological, chemical, or diagnostic reagents for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, for laboratory and research use

Scientific laboratory services, namely, detection and identification of cells, proteins, small molecules, and nucleotides in a sample for scientific, research, and technological purposes; Medical laboratory services, namely, providing medical diagnostic assays and diagnostic and prognostic testing for medical research purposes of infectious and residual disease, and the analysis, evaluation, and reporting of those test results to help healthcare professionals for research purposes; Development of new technology for others in the fields of biotechnology, DNA, RNA, small molecules, proteins, and nucleotide analysis services for scientific research purposes; Providing medical and scientific research information in the field of clinical trials, assays and assay development, diagnostics, cancer, RNA, DNA, small molecules, proteins, and nucleotides; Research and development in the medical and digital diagnostics and biotechnology fields; Custom design and development of chemical reagents and biochemical assays; Laboratory research in the field of oncology, hematology, and infectious diseases

Medical services; Medical assistance; Medical consultations; Medical counseling; Medical information; Healthcare services, namely, the diagnosis of diseases, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic services, namely, medical testing for diagnostic purposes; Wellness services, namely, providing wellness information in the fields of health and wellness; Medical services for the detection and identification of cells, proteins, small molecules, and nucleic acids in a sample in the nature of medical testing for diagnostic or treatment purposes

Medical diagnostic apparatus for testing cells, tissue, biomolecules, proteins, small molecules, and nucleotides; Medical devices for obtaining bodily fluid samples; Medical diagnostic instruments for the analysis of bodily fluids; Medical apparatus for diagnostic use, namely, medical apparatus for diagnostic testing of health conditions, diseases, or abnormalities, namely, in the fields of cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, genetic diseases, and endocrine diseases, and other tissue-based diagnostic testing, cytology, and cell based testing; Medical apparatus, devices, and instruments for wellness testing, health condition testing, and healthcare testing, namely, point-of-care diagnostic devices, at-home diagnostic devices, and portable health monitoring devices that detect health conditions and diseases in the nature of cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases and genetic diseases; Medical apparatus, devices, and instruments for the detection and identification of nucleic acids, namely, DNA and RNA in a sample, in the nature of apparatus for DNA and RNA testing for medical purposes

Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents and assays for testing cells, proteins, small molecules, nucleotides, and nucleic acids; Medical diagnostic reagents; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancers, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases; Diagnostic biomarker reagents for medical purposes; Biological and chemical test kits for personal wellness in the nature of diagnostic test kits consisting primarily of medical diagnostic reagents and assays for testing of bodily fluids and substances extracted from bodily fluids, namely, cells, proteins, small molecules, nucleotides, and nucleic acids for use in disease detection, namely, cancer, blood abnormalities, immune diseases, neurological diseases, cardiovascular diseases, infectious diseases, viral diseases, and genetic diseases

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 3, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 3, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 3, 2026 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 3, 2026 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 3, 2026 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 18, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 18, 2022 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 14, 2022 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 13, 2022 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 9, 2022 SUPC
USE AMENDMENT FILED
Aug 4, 2022 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 4, 2022 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 5, 2022 EXRA
SOU EXTENSION 4 GRANTED
Feb 3, 2022 EX4G
SOU EXTENSION 4 FILED
Feb 3, 2022 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 3, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 10, 2021 EXRA
SOU EXTENSION 3 GRANTED
Aug 9, 2021 EX3G
SOU EXTENSION 3 FILED
Aug 4, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 4, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 27, 2021 EXRA
SOU EXTENSION 2 GRANTED
Jan 25, 2021 EX2G
SOU EXTENSION 2 FILED
Jan 25, 2021 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 25, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 13, 2020 EXRA
SOU EXTENSION 1 GRANTED
Nov 12, 2020 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 9, 2020 AITU
NOTICE OF REVIVAL - E-MAILED
Sep 29, 2020 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Sep 29, 2020 TPEX
PETITION TO REVIVE-GRANTED
Sep 29, 2020 PETG
TEAS PETITION TO REVIVE RECEIVED
Sep 29, 2020 PROA
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 8, 2020 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 7, 2020 ABN6
SOU EXTENSION 1 FILED
Aug 4, 2020 EXT1
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 4, 2020 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 10, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 10, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 20, 2019 NONP
ASSIGNED TO LIE
Nov 7, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 4, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 4, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 4, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 4, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 4, 2019 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 8, 2019 GNRN
NON-FINAL ACTION E-MAILED
May 8, 2019 GNRT
NON-FINAL ACTION WRITTEN
May 8, 2019 CNRT
ASSIGNED TO EXAMINER
May 6, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 28, 2019 NWOS
NEW APPLICATION ENTERED
Mar 14, 2019 NWAP